NCT01431404已完成1 期
Randomized,Double-blind,Single-dosing,Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 With Active Comparator
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
研究概览
简要总结
The purpose of this study is compare the safety and pharmacokinetic characteristics of HD203 liquid with those of etanercept (enbrel) prefilled injection after subcutaneous injection.
详细描述
A randomized, double-blind, single-dosing, crossover study to compare the safety and pharmacokinetic characteristics of HD203 Liquid 25 mg with those of Enbrel Prefilled® injection 25 mg after subcutaneous injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •20 to 40 years of healthy volunteers
- •Weight over 55kg
- •Subject who signed on ICF
排除标准
- •Subject who had been treated with Etanercept before
结局指标
主要结局
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity
时间窗: up to 49days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male VolunteersHealthyNCT01894412Hanwha Chemical48
已完成
1 期
Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male VolunteersHealthyNCT01044836Hanwha Chemical42
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male VolunteersGrowth Hormone DeficiencyNCT01440686HanAll BioPharma Co., Ltd.40
已完成
1 期
A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male SubjectsHealthy VolunteersNCT03776240Prestige Biopharma Limited105
已完成
1 期
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy SubjectsADNCT03932916Shanghai Synergy Pharmaceutical Sciences Co., Ltd.38